Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 236,464,185 papers from all fields of science
Search
Sign In
Create Free Account
PF-2341066
Known as:
PF-02341066
, C-Met/Hepatocyte Growth Factor Receptor Tyrosine Kinase Inhibitor PF-02341066
, PF 2341066
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
crizotinib
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Immunohistochemical Evaluation Of ALK Expression In Breast Cancer
A. M. Bassam
,
Lubna O. Abdel-Salam
,
Dina A. Khairy
2015
Corpus ID: 212517033
Extensive studies are conducted to identify factors involved in breast cancer genesis and to understand the genetic and cellular…
Expand
2014
2014
Cancer Therapy : Preclinical Targeting Epithelial-to-Mesenchymal Transition with Met Inhibitors Reverts Chemoresistance in Small Cell Lung Cancer
F. Rojo
,
Á. Taus
,
+10 authors
E. Arriola
2014
Corpus ID: 20904074
Purpose: Met receptor phosphorylation is associated with poor prognosis in human small cell lung cancer (SCLC). The aim of our…
Expand
2013
2013
Amplification MET ( PF-02341066 ) in Gastric Cancer Positive for Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib
W. Okamoto
,
I. Okamoto
,
+7 authors
K. Nakagawa
2013
Corpus ID: 49530660
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the…
Expand
2012
2012
Preclinical Development Antitumor Action of the MET Tyrosine Kinase Inhibitor Crizotinib ( PF-02341066 ) in Gastric Cancer Positive for MET Ampli fi cation
W. Okamoto
,
I. Okamoto
,
+7 authors
K. Nakagawa
2012
Corpus ID: 8707180
Therapeutic strategies that target the tyrosine kinase MET hold promise for gastric cancer, but the mechanism underlying the…
Expand
2011
2011
Therapeutics , Targets , and Chemical Biology Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
C. Lovly
,
J. Heuckmann
,
+4 authors
W. Pao
2011
Corpus ID: 31131847
Aberrant forms of the anaplastic lymphoma kinase (ALK) have been implicated in the pathogenesis of multiple human cancers, where…
Expand
2011
2011
P3-18-01: cMET Inhibitor and the Inhibition of Growth of Breast Cancer Cells in Bone Marrow Matrix Environment.
L. Ye
,
Mason
,
P. Bramble
,
Wg. Jiang
2011
Corpus ID: 72032207
Background: Hepatocyte growth factor (HGF) is a cytokine that has a diverse but potential role in cancer including breast cancer…
Expand
2011
2011
Bresler Found in Neuroblastoma Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants
S. Bresler
,
A. Wood
,
+11 authors
Y. Mossé
2011
Corpus ID: 207790814
baby step toward improving crizotinib therapy in the clinic. a performed to find the maximum tolerated dose in the pediatric…
Expand
Review
2010
Review
2010
A target or a demi-target.
T. Mok
Clinical Lung Cancer
2010
Corpus ID: 35767462
Within only a decade, molecular targeted therapy has become a dominant feature in cancer research. Hundreds of novel molecules…
Expand
2010
2010
Structure of the Human Anaplastic Lymphoma Kinase in Complex with Crizotinib (PF-02341066)
M. McTigue
,
Y. Deng
,
+4 authors
J. Cui
2010
Corpus ID: 165042702
2010
2010
Another Targeted Therapy for Non–Small-Cell Lung Cancer?
Lin-Chi Chen
2010
Corpus ID: 80262656
Some patients with lung cancer have abnormalities in the anaplastic lymphoma kinase (ALK) protein. Investigators conducted a…
Expand